

ACTIVE SURVEILLANCE FOR LOW RISK PROSTATE CANCER

21-22 February 2014
Amsterdam, The Netherlands

Chairs: C.H. Bangma, NL - J. Hugosson, SE

Co-Chair: L. Klotz, CA

Honorary Chair: L.J. Denis, BE

ESO Prostate Cancer Programme Coordinator:
R. Valdagni, IT

Scientific Coordinators: M.J. Roobol, NL - S. Carlsson, SE/US

In collaboration with



Endorsed by



FOREWORD

Over the years, there has been increasing acceptance of active surveillance as an alternative to radical treatment for men with low risk prostate cancer. Unless the over-diagnosis of indolent prostate cancer is reduced by alternative diagnostic strategies, active surveillance will continue to play an important role. The challenge is to determine how new imaging methods and biomarkers can improve patient selection and how to incorporate drugs into active surveillance programmes.

ESO's second Inside Track Conference "Active surveillance for Low Risk Prostate Cancer", organized in collaboration with EAU and endorsed by Europa Uomo, aims at being an interactive educational activity in which attendees will enjoy presentations by internationally renowned researchers on active surveillance, who have helped develop and evaluate technologies that may change the selection and monitoring of patients.

Furthermore workshops will allow you to discuss a few selected hot topics with the top experts in that field. The remarks and conclusions of the workshops will give important insights into active surveillance practices applied in various countries.

When completing your registration form you will be asked to choose which workshop you would like to attend.

We would like to thank the European Association of Urology (EAU) and Europa Uomo for their participation and also, on behalf of the Scientific Coordinators, the Co-Chair, and the organizing team, we invite you to participate and contribute to a productive and enjoyable conference

Chris Bangma

Chair

Jonas Hugosson

Chair

Riccardo Valdagni

ESO Prostate Cancer

Programme Coordinator

FACULTY

C.H. Bangma

Department of Urology, Erasmus Medical Center, Rotterdam, NL

L. Bellardita

Prostate Cancer Programme, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT

A. Briganti

Urological Institute, Ospedale San Raffaele, Milan, IT

S. Carlsson

Department of Surgery and Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, US and Sahlgrenska Academy at the University of Göteborg, SE

P.R. Carroll

Department of Urology, UCSF School of Medicine, San Francisco, US

L.J. Denis

Europa Uomo, Oncology Center Antwerp, BE

G. Feick

Europa Uomo, Antwerp, BE

J. Hugosson

Department of Urology, Sahlgrenska Academy at the University of Göteborg, SE

G. Jenster

Department of Urology, Erasmus Medical Center, Rotterdam, NL

Y. Kakehi

Department of Urology, Kagawa University Faculty of Medicine, Kagawa, JP

L.H. Klotz

Division of Urology, Sunnybrook Health Sciences Centre, Toronto, CA

I. Korfage

Division of Epidemiology, Department of Public Health, Erasmus Medical Center, Rotterdam, NL

A. Lane

School of Social and Community Medicine, University of Bristol, Bristol, UK

C. Moore

Division of Surgical and Interventional Science, University College London, London, UK

T. Pickles

Department of Radiation, British Cancer Agency, Vancouver, CA

H. Randsdorp

Europa Uomo, Antwerp, BE

A. Rannikko

Department of Urology, Helsinki University Hospital, Helsinki, FI

S. Roemeling

Department of Urology, University Medical Center, Groningen, NL

M.J. Roobol

Department of Urology, Erasmus University Medical Center, Rotterdam, NL

E. Steyerberg

Department of Public Health, Erasmus Medical Center, Rotterdam, NL

B.J. Trock

Department of Urology, Johns Hopkins School of Medicine, Baltimore, US

R. Valdagni

ESO Prostate Cancer Programme

Prostate Cancer Programme and Division of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT

R. Van den Bergh

Department of Urology, University Medical Centre, Utrecht, NL

H. Van der Poel

Department of Urology, Netherlands Cancer Institute, Amsterdam, NL

H. Van Poppel

Department of Urology, University Hospital of the KU, Leuven, BE

A. Villers

Department of Urology, Hôpital Huriez, Centre Hospitalier Regional Universitaire, Lille, FR

H. Wijkstra

Department of Urology, Academic Medical Center University Hospital, Amsterdam, NL

PROGRAMME

FRIDAY, 21 FEBRUARY

- 8:00 *Registration*
- 9:00 **Welcome and objectives** C.H. Bangma, NL
J. Hugosson, SE
- 9:10 **Prostate Cancer Programme - European School of Oncology** R. Valdagni, IT

OVER-DETECTION AND OVER-TREATMENT

Chairs: J. Hugosson, SE - B. Trock, US

- 9:20 **Setting the stage: over-detection in cancer** J. Hugosson, SE
- 9:35 **How to reduce the number needed to treat in prostate cancer screening** M.J. Roobol, NL

SELECTION AND MONITORING FOR ACTIVE SURVEILLANCE

Chairs: P. Carroll, US - Y. Kakehi, JP

- 9:50 **Repeated biopsies: complications** A. Rannikko, FI
- 10:10 **How accurately can MRI detect indolent disease?** A.Villers, FR
- 10:30 *Coffee break*
- 10:50 **Triggers for reclassification in ongoing studies** L. Klotz, CA
- 11:10 **The image based targeted biopsy: what are criteria of indolence?** C. Moore, UK
- 11:40 **Contrast enhanced ultrasound. Toy or tool?** H. Wijkstra, NL
- 12:00 **How to evaluate intermediate outcomes in men for active surveillance?** P. Carroll, US
- 12:20 **Panel discussion: pitfalls and criticism of active surveillance**
Chairs: P. Carroll, US - C. Moore, UK
Panelists: A. Briganti, IT - L. Klotz, CA - A. Rannikko, FI - A.Villers, FR - H. Wijkstra, NL
Questions and answers
- 12:50 *Lunch and Poster Session*
- 14:00 **Best poster presentations**
14:00 *First poster*
14:10 *Second poster*

APPLICATION OF EMERGING TECHNOLOGY AND BIOMARKERS FOR SCREENING, SURVEILLANCE AND TREATMENT

Chairs: T. Pickles, CA - A. Rannikko, FI

- 14:30 **Biomarkers of indolent and aggressive prostate cancer - Application to active surveillance** B. Trock, US
- 14:50 **Genomic and transcriptomic fingerprinting of prostate biopsies** G. Jenster, NL
- 15:10 **Risk based prediction models for indolence: what is needed to incorporate new parameters?** E. Steyerberg, NL
- 15:30 **Can MRI replace serial biopsies, and how to prove that?** C. Moore, UK
- 15:50 **Panel discussion: Emerging technology and biomarkers: indolent or aggressive disease?**
Chairs: T. Pickles, CA - A. Rannikko, FI
Panelists: B. Trock, US - G. Jenster, NL - E. Steyerberg, NL - C. Moore, UK
Questions and answers
- 16:15 *Coffee break*
- 16:30 **Panel discussion: When to change current active surveillance protocols?**
Chairs: C.H. Bangma, NL - J. Hugosson, SE
Panelists: Y. Kakehi, JP - L. Klotz, CA - T. Pickles, CA - M.J. Roobol, NL - R. Valdagni, IT
- 17:20 **Posters viewing**

SATURDAY, 22 FEBRUARY

EAU LECTURE

Chairs: H. Van Poppel, B - R. Valdagni, IT

8:00 **Focal therapy vs active surveillance** H. Van der Poel, NL

THE QUALITY OF LIFE OF MEN ON ACTIVE SURVEILLANCE

Chairs: L. Bellardita IT - H. Randsdorp, BE - S. Roemeling, NL

8:45 **Quality of life outcome in active surveillance PRIAS - The Netherlands** I. Korfage, NL

9:05 **Living with untreated prostate cancer: predictors of poor quality of life - PRIAS Quality of Life Study at Milan National Cancer Institute** L. Bellardita, IT

9:25 **Men's experience of long term active surveillance - The PROTECT trial** A. Lane, UK

9:45 **The patients' perspective on active surveillance - The European Support** G. Feick, BE

10:00 **Panel discussion: Discussion by all Consensus building**

Chairs: C.H. Bangma, NL - J. Hugosson, SE

Questions and answers

10:30 *Coffee break*

10:45 **Movember Lecture - "The global action programme dealing with active surveillance"** C.H. Bangma, NL

11:05 **Simultaneous Workshops**

Workshop #1

Patient selection for active surveillance based on indolent disease definitions

(S. Carlsson US/SE - E. Steyerberg, NL)

Workshop #2

Overview of the global active surveillance studies / ongoing protocols

(B. Trock, US - R. Van den Bergh, NL)

Workshop #3

Randomized clinical trials - How to incorporate agents into active surveillance programmes

(C.H. Bangma, NL - Y. Kakehi, JP)

Workshop #4

How to measure patient's considerations and QoL in active surveillance programmes world wide

(L. Bellardita, IT - H. Randsdorp, BE)

Workshop #5

What studies need to be done to define indolence by emerging technology and biomarkers?

(C. Moore, UK - L. Klotz, CA)

13:00 *Lunch*

14:00 **Reports from individual Working Groups and Discussion**

Chair: P. Carroll, US - E. Steyerberg, NL

15:40 **Discussion by all - Consensus building**

16:30 **Closing remarks** C.H. Bangma, NL
J. Hugosson, SE

ABSTRACT SUBMISSION

Deadline for submission: 10 December 2013

Submit online at www.eso.net

Participants are invited to submit an abstract on research relating to the identification of potential indolent prostate cancer or on clinical studies relating to active surveillance of prostate cancer.

Abstracts will be considered for poster presentations only, except the two best abstracts posters which will be presented both as posters and as a 10-minute oral presentation on Friday, 21 February 2013. The two best abstracts will furthermore be awarded a prize of € 200.

Ample opportunity will be given to the conference participants to view all posters. The Chair of the Poster Session will visit all posters and participants will be able to give a short oral explanation of the research described (no slides). The Poster Session is scheduled on day, time.

Accepted abstracts will be published in the event's dedicated website.

GUIDELINES

- The abstracts should be limited to 2000 characters, including the title.
- The title should be in lower case letters
- Each author should be listed with First name, followed by Family Name
- The first author should be underlined (first author = corresponding author and presenter)
- List affiliation after the author's list
- The full address with e-mail address, phone and fax number of the first author (+corresponding author and presenter) must be provided. The first author will receive an acknowledgment of receipt and all subsequent communication by e-mail
- For abstracts accepted for poster presentation and best abstract oral presentation, the first author will be the presenting author and is requested to register and participate in the Conference
- It is responsibility of the first author to ascertain whether all authors are aware of the content of the abstract before submission is made

The acknowledgement of receipt of abstract will follow the submission. The abstract submission outcome will be notified by 13 December 2013 to the first author who will be required to register to the Conference (early registration deadline, 20 December 2013).

ESTRO Multidisciplinary Teaching Course on Prostate Cancer Amsterdam, 23-26 February 2014

Thanks to ESO-ESTRO collaboration, the ESTRO Multidisciplinary Teaching Course on Prostate Cancer will also be held in Amsterdam on the days following the ESO Conference "Active Surveillance for Low Risk Prostate Cancer", offering a unique opportunity to participants to attend both educational events.

The Course, chaired by Alberto Bossi (FR) and Alberto Briganti (IT) will discuss the management of localized, locally advanced and disseminated prostate cancer. It stresses the importance of multidisciplinary teamwork, where each sub-discipline is interrelated and information exchange is vital.

Participants attending both the ESO Conference and the ESTRO Course will benefit from reciprocal discounts on the registration fees.

Specifically, participants who are registered at the ESTRO Course will be granted the fee of EUR 200 (by the early rate deadline) to register for the ESO Conference. Reciprocally, participants registered at the ESO Conference will be granted the fee of EUR 450 to register to the ESTRO Course.

Further information on the Course are available at: <http://www.estro.org>



GENERAL INFORMATION

ORGANISING SECRETARIAT

Prostate Cancer Programme
European School of Oncology (ESO)
Via Turati 29 - 20121 Milan, Italy
Website: www.eso.net

VENUE

Beurs van Berlage
Damrak 243 - 1012 ZJ Amsterdam, NL
www.beursvanberlage.nl
*Beurs van Berlage is in a 5 minutes walk
from the Amsterdam railway station.*

Programme, organisation and abstracts:

Rita De Martini (prostate@eso.net) - Tel: +39 02 85464527 - Fax: +39 02 85464545

Registrations:

Elena Fiore (efiore@eso.net) - Tel. + 39 02 85464529 - Fax: +39 02 85464545

Hotel Accommodation:

MCI Amsterdam's Hotel Operations team at: aslrcp2014-hotels@mci-group.com
Tel: + 31 (0)20 6793411 - Fax: +31 (0) 20 6737306

ONLINE REGISTRATION

Registration may be carried out online at www.eso.net or
by returning the enclosed registration form

REGISTRATION

The registration fee includes participation in all sessions, coffee breaks and lunches, and a copy of the Programme booklet. Registration will be confirmed by e mail or by fax.

	Early (by 20 December 2013)	Late (by 20 January 2014)	On site (from 21 January 2014)
Registration fee	EUR 250	EUR 350	EUR 450
Club ESO Members	EUR 200		
ESTRO Course Participants	EUR 200		
EAU Members	EUR 200		
Trainees*	EUR 120	EUR 120	

*(a supporting letter of Dept. Director is required)

CANCELLATION OF REGISTRATION OR REPLACEMENT

Cancellations should be notified to ESO in writing by 20 January 2014. Replacement is allowed if written communication is received by 20 January 2014. In case of cancellation without replacement, the fee, less handling charges of EUR 100, will be refunded after the event.

CME ACCREDITATION

Application for CME recognition will be submitted to the Accreditation Council of Oncology in Europe (ACOE) and to the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). EACCME credits are recognised by the American Medical Association towards the Physician's Recognition Award (PRA).

Information on the status of the application can be obtained from the organising secretariat.

HOTEL ACCOMMODATION

If you require hotel accommodation in Amsterdam, please fill in the enclosed Hotel Accommodation Form and send it to MCI Amsterdam Hotel Reservations by e mail or by fax or book the hotel via ESO website at www.eso.net.

Hotel booking conditions

A full pre-payment by credit card, non refundable, is needed when booking. Availability is guaranteed until 20 January 2014. After that date, rooms will be provided upon request and based on availability.

OFFICIAL LANGUAGE

The official language of the Conference is English. No simultaneous translation will be provided.

BADGE

Your name badge is the only official evidence of registration and should be worn at all times during the Conference.

INSURANCE

The organisers bear no responsibility for untoward events in relation with the participation at the Conference. Participants are advised to take out their own personal and travel insurance coverage.

REGISTRATION FORM

ACTIVE SURVEILLANCE FOR LOW RISK PROSTATE CANCER, 21-22 FEBRUARY 2014, Amsterdam, NL

Please fill in this form in **BLOCK LETTERS** and send by the deadline to:
European School of Oncology - Via Turati 29 - 20121 Milan - Italy - Fax: +39 02 85464545 - E mail: efiore@eso.net

ONLINE REGISTRATION IS AVAILABLE AT: WWW.ESO.NET

PARTICIPANT'S DETAILS

Dr. Prof. Mrs. Mr.

Surname Name

Institute

Department

Street

Zip Code Town Country

Phone Fax Mobile

Email

Date of birth Birth date (town and country)

Profession

Specialisation Main field

VAT number (*compulsory for self-employed persons*)

Fiscal code (*Italian residents only*)

If your invoice details are different to those above, please complete the following section:

Invoice contact details

Address

Phone email

VAT number (*compulsory for self-employed persons*)

Fiscal Code (*Italian residents only*)

For organisation purposes, please select the workshop that you will attend:

Workshop N.1 Workshop N.2 Workshop N.3 Workshop N.4 Workshop N.5

REGISTRATION FEES:

Early

(by 20 December 2013)

Late

(by 20 January 2014)

Registration fee EUR 250

EUR 350

Club ESO Members EUR 200

EUR 350

ESTRO Course Participants EUR 200

EUR 350

EAO Members EUR 200

EUR 350

Trainees* EUR 120

EUR 120

**(a supporting letter of Dept. Director is required)*

PAYMENT DETAILS:

The registration is processed when payment accompanies the form (*credit card details or copy of bank transfer*)

Visa/Mastercard Card Number _____ / _____ / _____ / _____

Expire date _____ / _____ CV2 code _____

Holder's name (in CAPITAL LETTERS): _____ and signature

BANK TRANSFER with no cost to the beneficiary (please provide a copy of the bank transfer):

Bank: Banca Popolare di Milano, Agenzia 24 - Milan, Italy

Account holder: European School of Oncology

Number: No. 16333

IBAN: IT96G0558401624 0000000 16333 - **BIC:** BPMIIT1024


Reference: "Active Surveillance Conference 2014" + your name

I authorize the European School of Oncology to use my personal data according to what is specified in Article 13 DLGS 196, available at www.eso.net or on request at fax number +39 02 8546 4545.

Signature Date

HOTEL ACCOMMODATION

MCI Amsterdam, the official housing partner for “Active Surveillance for Low Risk Prostate Cancer”, has reserved a number of hotel rooms in three hotels in different price categories. These hotels are located in the city centre of Amsterdam, and the Beurs van Berlage (meeting venue) can easily be reached from all hotels.



Hotel name	Colour in map	Category	Room rate	Distance to the venue
Ibis Amsterdam Centre	blue	3 ★★ ★	€ 109	8 min walking
Mercure Amsterdam Arthur Frommer	red	4 ★★ ★ ★	€ 129	20 min walking or 10 min by public transportation
Mgallery The Convent Amsterdam	green	4 ★★ ★ ★	€ 144	5 min walking

 **Venue: Beurs van Berlage**

Above rates are based on single occupancy, include breakfast and exclude 5,5% city tax.

Ibis Amsterdam Centre

Ibis Amsterdam Centre is situated by the main train station. Trains, metros, buses, trams and taxis all drop you right to the door. Schiphol airport is just 15 minutes away by train, the Beurs van Berlage less than 10 minutes walking. The hotel offers 363 rooms, including 3 for disabled guests.



Mercure Amsterdam Arthur Frommer

The charming Hotel Mercure Amsterdam Arthur Frommer was refurbished in 2008. It is situated on a quiet street in the heart of Amsterdam, within walking distance of numerous shops, restaurants, museums and visitor attractions. The hotel has tastefully designed rooms and bathrooms, a bar, a breakfast room and a limited number of private parking spaces available (at a surcharge).



MGallery The Convent Amsterdam

The Convent Hotel Amsterdam is a 4-star hotel with a unique history that makes it the perfect place to stay. Its location in the centre of Amsterdam is ideal for visiting the city. It is a five-minute walk from Central Station, Dam Square and the Royal Palace. The hotel building previously housed 2 monasteries from the 13th & 14th centuries, plus a printing house.



HOTEL BOOKING CONDITONS

A full prepayment by credit card, non-refundable, is needed when booking online. Availability is guaranteed until 20 January 2014. After that date, rooms will be provided upon request and based on availability.

Should you have any questions regarding hotel accommodation, please do not hesitate to contact MCI Amsterdam's Hotel Operations team at: asrlpc2014-hotels@mci-group.com

Hotel Reservations team:

MCI-Eurocongress vof - Jan van Goyenkade 11 - 1075 HP Amsterdam
Tel.: +31 (0)20 6793411 - Fax: +31 (0)20 6737306 - E-mail: asrlpc2014-hotels@mci-group.com

HOTEL ACCOMMODATION FORM

ACTIVE SURVEILLANCE FOR LOW RISK PROSTATE CANCER

21-22 FEBRUARY 2014, Amsterdam, The Netherlands

Please complete this form using **CAPITAL** letters and send to **Hotel Reservations at MCI Amsterdam**
Fax: +31 (0)20 673 7306 - E-mail: asrlpc2014-hotels@mci-group.com

For online accommodation bookings and more information on the hotels, please go to www.eso.net

PARTICIPANT'S INFORMATION

Surname	First Name
Organization	
Address	
City	Postcode/Zipcode
State/County	Country
Email	
Tel <i>(including country code)</i>	Fax <i>(including country code)</i>

RESERVATION

All rates quoted are based on single occupancy, including breakfast and excluding 5,5% city tax

Ibis Amsterdam Centre (★★★) € 109 per room per night

Mercure Amsterdam Arthur Frommer (★★★★) € 129 per room per night

Mgallery The Convent Amsterdam (★★★★) € 144 per room per night

Check in date _____

Check out date _____

Sharing with *(only if double occupancy)* _____

Please indicate any special requests _____

TERMS AND CONDITIONS

Full pre-payment required at the time of booking. Please note it is not possible to cancel or modify the booking once you have received the confirmation of your reservation.

CREDIT CARD DETAILS

Accommodation payment needs to be done at the time of reservation and extras will be paid directly to the hotel. Please provide your credit card details (Mastercard or Visa Card only); without credit card details it will not be possible to make a reservation.

CREDIT CARD Mastercard Visa Card

Credit Card number _____ / _____ / _____ / _____ Exp. Date _____ / _____

Card holder's name *(in Capital letters)* _____ CVW number _____

Card holder's signature _____

I agree to the terms and conditions and that my credit card details will be used for payment and confirming the reservation.

Signature _____

If you require any assistance with your booking please do not hesitate to contact the Hotel Reservations team at: Tel: +31 (0)20 679 3411 - E-mail: asrlpc2014-hotels@mci-group.com